DT-Web

DB00543 - Amoxapine


Identification
Name Amoxapine
Accession Number DB00543 (APRD00142)
Type small molecule
Description Amoxapine, the N-demethylated derivative of the antipsychotic agent loxapine, is a dibenzoxazepine-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, amoxapine does not affect mood or arousal, but may cause sedation. In depressed individuals, amoxapine exerts a positive effect on mood. TCAs are potent inhibitors of serotonin and norepinephrine reuptake. In addition, TCAs down-regulate cerebral cortical β-adrenergic receptors and sensitize post-synaptic serotonergic receptors with chronic use. The antidepressant effects of TCAs are thought to be due to an overall increase in serotonergic neurotransmission. TCAs also block histamine H1 receptors, α1-adrenergic receptors and muscarinic receptors, which accounts for their sedative, hypotensive and anticholinergic effects (e.g. blurred vision, dry mouth, constipation, urinary retention), respectively. See toxicity section below for a complete listing of side effects. Amoxapine may be used to treat neurotic and reactive depressive disorders, endogenous and psychotic depression, and mixed symptoms of depression and anxiety or agitation.
Structure
MOL SDF PDB SMILES InChI
Categories (*)
Molecular Weight 313.781
Groups approved
Monoisotopic Weight 313.098189856
Pharmacology
Indication For the relief of symptoms of depression in patients with neurotic or reactive depressive disorders as well as endogenous and psychotic depressions. May also be used to treat depression accompanied by anxiety or agitation.
Mechanism of action Amoxapine acts by decreasing the reuptake of norepinephrine and serotonin (5-HT).
Absorption Rapidly and almost completely absorbed from the GI tract. Peak plasma concentrations occur within 1-2 hours of oral administration of a single dose.
Protein binding In vitro tests show that amoxapine binding to human plasma proteins is approximately 90%.
Biotransformation Amoxapine is almost completely metabolized in the liver to its major metabolite, 8-hydroxyamoxapine, and a minor metabolite, 7-hydroxyamoxapine. Both metabolites are phamacologically inactive and have half-lives of approximately 30 and 6.5 hours, respectively.
Route of elimination 60-69% of a single orally administered dose of amoxapine is excreted in urine, principally as conjugated metabolites. 7-18% of the dose is excrete feces mainly as unconjugated metabolites. Less than 5% of the dose is excreted as unchanged drug in urine.
Toxicity Toxic manifestations of amoxapine overdosage differ significantly from those of other tricyclic antidepressants. Serious cardiovascular effects are seldom if ever observed. However, CNS effects, particularly grand mal convulsions, occur frequently, and treatment should be directed primarily toward prevention or control of seizures. Status epilepticus may develop and constitutes a neurologic emergency. Coma and acidosis are other serious complications of substantial amoxapine overdosage in some cases. Renal failure may develop two to five days after toxic overdose in patients who may appear otherwise recovered. Acute tubular necrosis with rhabdomuolysis and myolobinurla is the most common renal complication in such cases. This reaction probably occurs in less than 5% of overdose cases, and typically in those who have experienced multiple seizures.
Affected organisms
  • Humans and other mammals
Interactions
Drug Interactions
Drug Mechanism of interaction
Altretamine Risk of severe hypotension
Artemether Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
Atazanavir Atazanavir may increase the effect and toxicity of the tricyclic antidepressant, amoxapine, by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of amoxapine if atazanavir if initiated, discontinued or dose changed.
Butabarbital Barbiturates like butabarbital may increase the metabolism of tricyclic antidepressants like amoxipine. Monitor for decreased therapeutic effects of tricyclic antidepressants if a barbiturate is initiated/dose increased, or increased effects if a barbiturate is discontinued/dose decreased. The tricyclic antidepressant dosage will likely need to be increased during concomitant barbiturate therapy, and reduced upon barbiturate discontinuation.
Butalbital Barbiturates such as butalbital may increase the metabolism of tricyclic antidepressants amoxapine. Monitor for decreased therapeutic effects of tricyclic antidepressants if a barbiturate is initiated/dose increased, or increased effects if a barbiturate is discontinued/dose decreased. The tricyclic antidepressant dosage will likely need to be increased during concomitant barbiturate therapy, and reduced upon barbiturate discontinuation.
Cimetidine Cimetidine may increase the effect of the tricyclic antidepressant, amoxapine, by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of amoxapine if cimetidine is initiated, discontinued or dose changed.
Cisapride Increased risk of cardiotoxicity and arrhythmias
Clonidine The tricyclic antidepressant, amoxapine, decreases the effect of clonidine.
Desvenlafaxine Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
Dobutamine The tricyclic antidepressant, amoxapine, increases the sympathomimetic effect of dobutamine.
Donepezil Possible antagonism of action
Dopamine The tricyclic antidepressant, amoxapine, increases the sympathomimetic effect of dopamine.
Ephedra The tricyclic antidepressant, amoxapine, increases the sympathomimetic effect of ephedra.
Ephedrine The tricyclic antidepressant, amoxapine, increases the sympathomimetic effect of ephedrine.
Epinephrine The tricyclic antidepressant, amoxapine, increases the sympathomimetic effect of epinephrine.
Fenoterol The tricyclic antidepressant, amoxapine, increases the sympathomimetic effect of fenoterol.
Fluoxetine The SSRI, fluoxetine, may increase the serum concentration of the tricyclic antidepressant, amoxapine, by decreasing its metabolism. Additive modulation of serotonin activity also increases the risk of serotonin syndrome. Monitor for development of serotonin syndrome during concomitant therapy. Monitor for changes in the therapeutic and adverse effects of amoxapine if fluoxetine is initiated, discontinued or dose changed.
Fluvoxamine The SSRI, fluvoxamine, may increase the serum concentration of the tricyclic antidepressant, amoxapine, by decreasing its metabolism. Additive modulation of serotonin activity also increases the risk of serotonin syndrome. Monitor for development of serotonin syndrome during concomitant therapy. Monitor for changes in the therapeutic and adverse effects of amoxapine if fluvoxamine is initiated, discontinued or dose changed.
Galantamine Possible antagonism of action
Grepafloxacin Increased risk of cardiotoxicity and arrhythmias
Guanethidine The tricyclic antidepressant, amoxapine, decreases the effect of guanethidine.
Isocarboxazid Possibility of severe adverse effects
Isoproterenol The tricyclic antidepressant, amoxapine, increases the sympathomimetic effect of isoproterenol.
Lumefantrine Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
Mephentermine The tricyclic antidepressant, amoxapine, increases the sympathomimetic effect of mephentermine.
Metaraminol The tricyclic antidepressant, amoxapine, increases the sympathomimetic effect of metaraminol.
Methoxamine The tricyclic antidepressant, amoxapine, increases the sympathomimetic effect of methoxamine.
Moclobemide Possible severe adverse reaction with this combination
Norepinephrine The tricyclic antidepressant, amoxapine, increases the sympathomimetic effect of norepinephrine.
Orciprenaline The tricyclic antidepressant, amoxapine, increases the sympathomimetic effect of orciprenaline.
Phenelzine Possibility of severe adverse effects
Phenylephrine The tricyclic antidepressant, amoxapine, increases the sympathomimetic effect of phenylephrine.
Phenylpropanolamine The tricyclic antidepressant, amoxapine, increases the sympathomimetic effect of phenylpropanolamine.
Pirbuterol The tricyclic antidepressant, amoxapine, increases the sympathomimetic effect of pirbuterol.
Procaterol The tricyclic antidepressant, amoxapine, increases the sympathomimetic effect of procaterol.
Pseudoephedrine The tricyclic antidepressant, amoxapine, increases the sympathomimetic effect of pseudoephedrine.
Rasagiline Possibility of severe adverse effects
Rifabutin The rifamycin, rifabutin, may decrease the effect of the tricyclic antidepressant, amoxapine, by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of amoxapine if rifabutin is initiated, discontinued or dose changed.
Rifampin The rifamycin, rifampin, may decrease the effect of the tricyclic antidepressant, amoxapine, by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of amoxapine if rifampin is initiated, discontinued or dose changed.
Ritonavir Ritonavir may increase the effect and toxicity of the tricyclic antidepressant, amoxapine, by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of amoxapine if ritonavir if initiated, discontinued or dose changed.
Rivastigmine Possible antagonism of action
Salbutamol The tricyclic antidepressant, amoxapine, increases the sympathomimetic effect of salbutamol.
Sibutramine Increased risk of CNS adverse effects
Sparfloxacin Increased risk of cardiotoxicity and arrhythmias
Tacrine The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Amoxapine, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents.
Tacrolimus Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.
Terbinafine Terbinafine may reduce the metabolism and clearance of Amoxapine. Consider alternate therapy or monitor for therapeutic/adverse effects of Amoxapine if Terbinafine is initiated, discontinued or dose changed.
Terbutaline The tricyclic antidepressant, amoxapine, increases the sympathomimetic effect of terbutaline.
Terfenadine Increased risk of cardiotoxicity and arrhythmias
Thiothixene May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration.
Toremifene Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration.
Tramadol Tramadol increases the risk of serotonin syndrome and seizures.
Tranylcypromine Increased risk of serotonin syndrome. Concomitant therapy should be avoided. A significant washout period, dependent on the half-lives of the agents, should be employed between therapies.
Trazodone Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
Trimethobenzamide Trimethobenzamide and Amoxapine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects.
Trimipramine Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome. Additive QTc-prolongation may also occur, increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.
Triprolidine Triprolidine and Amoxapine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Additive CNS depressant effects may also occur. Monitor for enhanced anticholinergic and CNS depressant effects.
Trospium Trospium and Amoxapine, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects.
Venlafaxine Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
Voriconazole Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
Vorinostat Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
Ziprasidone Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated.
Zolmitriptan Use of two serotonin modulators, such as zolmitriptan and amoxapine, increases the risk of serotonin syndrome. Consider alternate therapy or monitor for serotonin syndrome during concomitant therapy.
Zuclopenthixol Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
Food Interactions
  • Take with food to reduce irritation.
  • Avoid alcohol.

Targets


Sodium-dependent noradrenaline transporter
Name Sodium-dependent noradrenaline transporter
Gene Name SLC6A2
Pharmacological action unknown
Actions inhibitor
References
  • Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. - Pubmed
  • Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. - Pubmed
  • Tatsumi M, Groshan K, Blakely RD, Richelson E: Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol. 1997 Dec 11;340(2-3):249-58. - Pubmed
DTHybrid score 0.5549
Sodium-dependent serotonin transporter
Name Sodium-dependent serotonin transporter
Gene Name SLC6A4
Pharmacological action yes
Actions inhibitor
References
  • Spurlock G, Buckland P, O'Donovan M, McGuffin P: Lack of effect of antidepressant drugs on the levels of mRNAs encoding serotonergic receptors, synthetic enzymes and 5HT transporter. Neuropharmacology. 1994 Mar-Apr;33(3-4):433-40. - Pubmed
  • Tatsumi M, Groshan K, Blakely RD, Richelson E: Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol. 1997 Dec 11;340(2-3):249-58. - Pubmed
DTHybrid score 0.4175
D(2) dopamine receptor
Name D(2) dopamine receptor
Gene Name DRD2
Pharmacological action unknown
Actions antagonist
References
  • Wei HB, Niu XY: [Comparison of the affinities of amoxapine and loxapine for various receptors in rat brain and the receptor down-regulation after chronic administration] Yao Xue Xue Bao. 1990;25(12):881-5. - Pubmed
  • Nasu R, Matsuo H, Takanaga H, Ohtani H, Sawada Y: Quantitative prediction of catalepsy induced by amoxapine, cinnarizine and cyclophosphamide in mice. Biopharm Drug Dispos. 2000 May;21(4):129-38. - Pubmed
DTHybrid score 0.4339
D(1A) dopamine receptor
Name D(1A) dopamine receptor
Gene Name DRD1
Pharmacological action unknown
Actions antagonist
References
  • Nasu R, Matsuo H, Takanaga H, Ohtani H, Sawada Y: Quantitative prediction of catalepsy induced by amoxapine, cinnarizine and cyclophosphamide in mice. Biopharm Drug Dispos. 2000 May;21(4):129-38. - Pubmed
DTHybrid score 0.3649
Alpha-2A adrenergic receptor
Name Alpha-2A adrenergic receptor
Gene Name ADRA2A
Pharmacological action unknown
Actions antagonist
References
  • Richelson E, Nelson A: Antagonism by antidepressants of neurotransmitter receptors of normal human brain in vitro. J Pharmacol Exp Ther. 1984 Jul;230(1):94-102. - Pubmed
  • Buckley NA, McManus PR: Can the fatal toxicity of antidepressant drugs be predicted with pharmacological and toxicological data? Drug Saf. 1998 May;18(5):369-81. - Pubmed
DTHybrid score 0.4486
Alpha-1A adrenergic receptor
Name Alpha-1A adrenergic receptor
Gene Name ADRA1A
Pharmacological action unknown
Actions antagonist
References
  • Wei HB, Niu XY: [Comparison of the affinities of amoxapine and loxapine for various receptors in rat brain and the receptor down-regulation after chronic administration] Yao Xue Xue Bao. 1990;25(12):881-5. - Pubmed
  • Buckley NA, McManus PR: Can the fatal toxicity of antidepressant drugs be predicted with pharmacological and toxicological data? Drug Saf. 1998 May;18(5):369-81. - Pubmed
DTHybrid score 0.5559
Muscarinic acetylcholine receptor M1
Name Muscarinic acetylcholine receptor M1
Gene Name CHRM1
Pharmacological action unknown
Actions antagonist
References
  • Richelson E: Antimuscarinic and other receptor-blocking properties of antidepressants. Mayo Clin Proc. 1983 Jan;58(1):40-6. - Pubmed
  • Buckley NA, McManus PR: Can the fatal toxicity of antidepressant drugs be predicted with pharmacological and toxicological data? Drug Saf. 1998 May;18(5):369-81. - Pubmed
DTHybrid score 0.4961
Gamma-aminobutyric-acid receptor subunit alpha-1
Name Gamma-aminobutyric-acid receptor subunit alpha-1
Gene Name GABRA1
Pharmacological action unknown
Actions antagonist
References
  • Buckley NA, McManus PR: Can the fatal toxicity of antidepressant drugs be predicted with pharmacological and toxicological data? Drug Saf. 1998 May;18(5):369-81. - Pubmed
DTHybrid score 0.2269

Enzymes


Cytochrome P450 2D6
Name Cytochrome P450 2D6
Gene Name CYP2D6
Actions substrate
References
  • Shin HC, Kim HR, Cho HJ, Yi H, Cho SM, Lee DG, El-Aty AM, Kim JS, Sun D, Amidon GL: Comparative gene expression of intestinal metabolizing enzymes. Biopharm Drug Dispos. 2009 Nov;30(8):411-21. - Pubmed
DTHybrid score 0.5797

Carriers


Predictions


Id Partner name Gene Name Score
4512 Cytochrome P450 3A4 CYP3A4 0.3623
502 5-hydroxytryptamine 2A receptor HTR2A 0.2969
713 Sodium-dependent dopamine transporter SLC6A3 0.2417
1588 Multidrug resistance protein 1 ABCB1 0.2192
632 Alpha-1B adrenergic receptor ADRA1B 0.2107
4200 Cytochrome P450 1A2 CYP1A2 0.2085
617 Muscarinic acetylcholine receptor M2 CHRM2 0.2006
51 Muscarinic acetylcholine receptor M3 CHRM3 0.1899
492 Histamine H1 receptor HRH1 0.1781
590 5-hydroxytryptamine 2C receptor HTR2C 0.172
320 5-hydroxytryptamine 1A receptor HTR1A 0.1699
6016 Cytochrome P450 2C19 CYP2C19 0.168
629 Alpha-2B adrenergic receptor ADRA2B 0.1634
4757 Cytochrome P450 2C9 CYP2C9 0.1591
378 Alpha-2C adrenergic receptor ADRA2C 0.1508
450 Muscarinic acetylcholine receptor M4 CHRM4 0.1358
274 Muscarinic acetylcholine receptor M5 CHRM5 0.1262
789 Alpha-1D adrenergic receptor ADRA1D 0.1216
432 D(4) dopamine receptor DRD4 0.1207
638 D(3) dopamine receptor DRD3 0.1204
163 D(1B) dopamine receptor DRD5 0.1143
587 Serum albumin ALB 0.1103
4118 Cytochrome P450 3A5 CYP3A5 0.1045
6030 Cytochrome P450 2B6 CYP2B6 0.1034
436 5-hydroxytryptamine 2B receptor HTR2B 0.1001
6013 Cytochrome P450 2E1 CYP2E1 0.0991
3941 Amine oxidase [flavin-containing] A MAOA 0.0932
4924 Cytochrome P450 2C8 CYP2C8 0.0916
131 Synaptic vesicular amine transporter SLC18A2 0.0912
6107 Cytochrome P450 3A7 CYP3A7 0.086
766 Beta-2 adrenergic receptor ADRB2 0.0817
193 Beta-1 adrenergic receptor ADRB1 0.0808
725 5-hydroxytryptamine 1D receptor HTR1D 0.0766
6145 Solute carrier family 22 member 1 SLC22A1 0.0756
885 5-hydroxytryptamine 1B receptor HTR1B 0.0727
523 Gamma-aminobutyric-acid receptor subunit alpha-5 GABRA5 0.0697
423 Gamma-aminobutyric-acid receptor subunit alpha-2 GABRA2 0.0696
580 Gamma-aminobutyric-acid receptor subunit alpha-3 GABRA3 0.0651
3939 Amine oxidase [flavin-containing] B MAOB 0.0607
716 5-hydroxytryptamine 7 receptor HTR7 0.0583
3923 Cholinesterase BCHE 0.0559
6024 Cytochrome P450 1A1 CYP1A1 0.0555
6144 Solute carrier family 22 member 2 SLC22A2 0.0511
530 Gamma-aminobutyric-acid receptor subunit alpha-4 GABRA4 0.0483
841 Gamma-aminobutyric-acid receptor subunit alpha-6 GABRA6 0.0479
220 Sodium channel protein type 5 subunit alpha SCN5A 0.045
465 Calmodulin CALM1 0.0431
1256 5-hydroxytryptamine 6 receptor HTR6 0.0386
6086 Gamma-aminobutyric acid receptor subunit gamma-2 GABRG2 0.0383
5718 Cytochrome P450 2A6 CYP2A6 0.0369
101 Potassium voltage-gated channel subfamily H member 2 KCNH2 0.0365
921 Glutamate receptor 2 GRIA2 0.0355
706 Glutamate [NMDA] receptor subunit 3A GRIN3A 0.0334
118 Organic cation/carnitine transporter 2 SLC22A5 0.0332
341 5-hydroxytryptamine 3 receptor HTR3A 0.0329
4095 Neuronal acetylcholine receptor subunit alpha-7 CHRNA7 0.0329
947 Neuronal acetylcholine receptor subunit alpha-4 CHRNA4 0.0329
6147 Solute carrier family 22 member 3 SLC22A3 0.0326
4100 Gamma-aminobutyric-acid receptor subunit beta-2 GABRB2 0.0317
918 Glutamate receptor, ionotropic kainate 2 GRIK2 0.0316
6106 Cytochrome P450 2C18 CYP2C18 0.0311
1732 ATP-binding cassette sub-family G member 2 ABCG2 0.0307
3876 Aromatic-L-amino-acid decarboxylase DDC 0.0304
401 Glutamate [NMDA] receptor subunit zeta-1 GRIN1 0.0299
1656 CYP2B protein CYP2B 0.0291
124 Histamine H2 receptor HRH2 0.0291
1517 Beta-3 adrenergic receptor ADRB3 0.0284
4099 Gamma-aminobutyric-acid receptor subunit beta-3 GABRB3 0.028
4098 Gamma-aminobutyric-acid receptor subunit beta-1 GABRB1 0.0275
142 Gamma-aminobutyric-acid receptor subunit rho-1 GABRR1 0.0272
6087 Gamma-aminobutyric acid receptor subunit gamma-1 GABRG1 0.0263
6093 Gamma-aminobutyric acid receptor subunit delta GABRD 0.0261
6089 Gamma-aminobutyric acid receptor subunit epsilon GABRE 0.0261
696 Kappa-type opioid receptor OPRK1 0.0256
528 5-hydroxytryptamine 1E receptor HTR1E 0.0248
6088 Gamma-aminobutyric acid receptor subunit gamma-3 GABRG3 0.024
6090 Gamma-aminobutyric acid receptor subunit pi GABRP 0.024
6092 Gamma-aminobutyric acid receptor subunit rho-2 GABRR2 0.0239
6115 Gamma-aminobutyric acid receptor subunit rho-3 GABRR3 0.0239
847 Mu-type opioid receptor OPRM1 0.0236
3426 Glutamine synthetase glnA 0.0224
3987 Glutamine synthetase GLUL 0.0224
833 Organic cation/carnitine transporter 1 SLC22A4 0.0223
20 Prostaglandin G/H synthase 1 PTGS1 0.0223
482 Glycine receptor subunit alpha-1 GLRA1 0.022
1636 Trace amine-associated receptor 1 TAAR1 0.0218
467 Delta-type opioid receptor OPRD1 0.0217
474 Acetylcholinesterase ACHE 0.0211
6099 Potassium voltage-gated channel subfamily D member 3 KCND3 0.0205
6098 Potassium voltage-gated channel subfamily D member 2 KCND2 0.0205
811 Translocator protein TSPO 0.019
6432 Transporter snf 0.0189
1539 Oligopeptide transporter, small intestine isoform SLC15A1 0.0187
734 D1 dopamine receptor-interacting protein calcyon CALY 0.0178
858 Potassium voltage-gated channel subfamily A member 1 KCNA1 0.0177
6018 UDP-glucuronosyltransferase 1-9 UGT1A9 0.0177
862 Multidrug resistance-associated protein 1 ABCC1 0.0173
787 Vitamin K epoxide reductase complex subunit 1 VKORC1 0.0163
514 Potassium voltage-gated channel subfamily H member 6 KCNH6 0.0161
772 Potassium voltage-gated channel subfamily H member 7 KCNH7 0.0161
240 Gamma-aminobutyric acid type B receptor, subunit 1 GABBR1 0.0151
380 Cytochrome P450 17A1 CYP17A1 0.0148
828 Phenylalanine-4-hydroxylase PAH 0.0147
3109 Phenylalanine-4-hydroxylase phhA 0.0147
6091 Gamma-aminobutyric acid receptor subunit theta GABRQ 0.0147
241 Calcium-transporting ATPase type 2C member 1 ATP2C1 0.0147
94 5-hydroxytryptamine 4 receptor HTR4 0.0147
6017 Cholesterol side-chain cleavage enzyme, mitochondrial CYP11A1 0.014
537 ATP synthase delta chain, mitochondrial ATP5D 0.014
6025 UDP-glucuronosyltransferase 1-4 UGT1A4 0.014
813 Neuronal acetylcholine receptor subunit alpha-2 CHRNA2 0.0137
6101 Dimethylaniline monooxygenase [N-oxide-forming] 3 FMO3 0.0135
705 Glutamate receptor 1 GRIA1 0.0132
559 NADH-ubiquinone oxidoreductase chain 1 MT-ND1 0.0132
5251 Carbonyl reductase [NADPH] 1 CBR1 0.0129
6104 Dimethylaniline monooxygenase [N-oxide-forming] 1 FMO1 0.0129
1735 Canalicular multispecific organic anion transporter 1 ABCC2 0.0127
6178 UDP-glucuronosyltransferase 2B7 UGT2B7 0.0126
6023 Cytochrome P450 11B2, mitochondrial CYP11B2 0.0126
844 Epidermal growth factor receptor EGFR 0.0124
805 Cytochrome P450 11B1, mitochondrial CYP11B1 0.0123
1632 Solute carrier organic anion transporter family member 2B1 SLCO2B1 0.012
6182 Cytochrome P450 2J2 CYP2J2 0.0119
6164 POU domain, class 5, transcription factor 1 POU5F1 0.0117
3810 Catechol O-methyltransferase COMT 0.0114
5878 Alpha-7 nicotinic cholinergic receptor subunit CHRFAM7A 0.0112
198 Sodium channel protein type 10 subunit alpha SCN10A 0.0112
750 Voltage-dependent calcium channel gamma-1 subunit CACNG1 0.0111
6139 Solute carrier organic anion transporter family member 1A2 SLCO1A2 0.0109
1898 Cytochrome P450 1B1 CYP1B1 0.0105
1490 Solute carrier organic anion transporter family member 1B1 SLCO1B1 0.0104
1757 Myeloperoxidase MPO 0.0101
6020 Aldehyde oxidase AOX1 0.0098
174 Sigma 1-type opioid receptor SIGMAR1 0.0093
776 Bile salt export pump ABCB11 0.0093
1618 High affinity nerve growth factor receptor NTRK1 0.0092
4115 Voltage-dependent L-type calcium channel subunit alpha-1D CACNA1D 0.0091
478 Voltage-dependent L-type calcium channel subunit alpha-1C CACNA1C 0.0089
6151 Monocarboxylate transporter 10 SLC16A10 0.0089
6100 BDNF/NT-3 growth factors receptor NTRK2 0.0087
2184 Cystic fibrosis transmembrane conductance regulator CFTR 0.0086
4209 ATP-sensitive inward rectifier potassium channel 8 KCNJ8 0.0085
215 Sodium channel protein type 11 subunit alpha SCN11A 0.0085
1360 Sphingomyelin phosphodiesterase SMPD1 0.0084
172 Potassium channel subfamily K member 1 KCNK1 0.0084
464 Glutamate [NMDA] receptor subunit epsilon-2 GRIN2B 0.0081
4120 NADPH--cytochrome P450 reductase POR 0.0081
439 Glutamate [NMDA] receptor subunit epsilon-4 GRIN2D 0.0078
2981 Phospholipase A2, membrane associated PLA2G2A 0.0076
6859 Protein S100-A4 S100A4 0.0076
781 ATP-sensitive inward rectifier potassium channel 11 KCNJ11 0.0075
6070 Nischarin NISCH 0.0075
6180 UDP-glucuronosyltransferase 2B4 UGT2B4 0.0075
6176 UDP-glucuronosyltransferase 1-3 UGT1A3 0.0074
4113 Voltage-dependent L-type calcium channel subunit alpha-1F CACNA1F 0.0074
923 Glutamate receptor 3 GRIA3 0.0074
158 Sodium channel protein type 1 subunit alpha SCN1A 0.0073
6079 Neuronal acetylcholine receptor subunit alpha-3 CHRNA3 0.0073
4111 Voltage-dependent L-type calcium channel subunit alpha-1S CACNA1S 0.0071
731 HIV-1 protease HIV-1 protease 0.0071
2164 Multidrug resistance-associated protein 4 ABCC4 0.0071
709 ATP-sensitive inward rectifier potassium channel 1 KCNJ1 0.0068
1050 Bile salt sulfotransferase SULT2A1 0.0067
4110 Voltage-dependent L-type calcium channel subunit beta-2 CACNB2 0.0066
1086 Potassium voltage-gated channel subfamily KQT member 2 KCNQ2 0.0066
6169 ATP-binding cassette sub-family A member 5 ABCA5 0.0066
698 B-Raf proto-oncogene serine/threonine-protein kinase BRAF 0.0065
866 Large neutral amino acids transporter small subunit 2 SLC7A8 0.0065
3947 Xanthine dehydrogenase/oxidase XDH 0.0064
820 Glycine receptor subunit alpha-2 GLRA2 0.0063
183 Vascular endothelial growth factor A VEGFA 0.0063
1561 Troponin C, slow skeletal and cardiac muscles TNNC1 0.0062
245 Large neutral amino acids transporter small subunit 1 SLC7A5 0.006
6022 UDP-glucuronosyltransferase 1-1 UGT1A1 0.0058
723 Cytosolic phospholipase A2 PLA2G4A 0.0057
3811 Cytochrome P450 19A1 CYP19A1 0.0055
164 Histamine H4 receptor HRH4 0.0055
1729 Solute carrier family 22 member 6 SLC22A6 0.0054
458 Neuronal acetylcholine receptor subunit alpha-10 CHRNA10 0.0052
5787 Angiopoietin-1 receptor TEK 0.0052
610 Calcium-activated potassium channel subunit alpha 1 KCNMA1 0.005
837 Glutamate [NMDA] receptor subunit epsilon-1 GRIN2A 0.005
1680 Solute carrier family 2, facilitated glucose transporter member 1 SLC2A1 0.0049
964 Voltage-dependent T-type calcium channel subunit alpha-1H CACNA1H 0.0049
2180 3-phosphoinositide-dependent protein kinase 1 PDPK1 0.0049
631 3-hydroxy-3-methylglutaryl-coenzyme A reductase HMGCR 0.0048
3387 3-hydroxy-3-methylglutaryl-coenzyme A reductase mvaA 0.0048
591 Glutamate [NMDA] receptor subunit 3B GRIN3B 0.0047
904 Glutathione S-transferase P GSTP1 0.0047
4112 Voltage-dependent L-type calcium channel subunit beta-4 CACNB4 0.0047
4114 Voltage-dependent L-type calcium channel subunit beta-3 CACNB3 0.0047
290 Prostaglandin G/H synthase 2 PTGS2 0.0046
15 Voltage-dependent T-type calcium channel subunit alpha-1I CACNA1I 0.0045
461 Glycine receptor subunit alpha-3 GLRA3 0.0045
382 Glutamate receptor, ionotropic kainate 1 GRIK1 0.0045
6157 Solute carrier organic anion transporter family member 1B3 SLCO1B3 0.0044
2112 Toll-like receptor 9 TLR9 0.0044
2129 Sucrase-isomaltase, intestinal SI 0.0043
768 FK506-binding protein 1A FKBP1A 0.0043
6138 Multidrug resistance protein 3 ABCB4 0.0043
535 Voltage-dependent T-type calcium channel subunit alpha-1G CACNA1G 0.0043
333 Voltage-dependent L-type calcium channel subunit beta-1 CACNB1 0.0042
505 Glutamate [NMDA] receptor subunit epsilon-3 GRIN2C 0.0041
468 Cytochrome P450 4A11 CYP4A11 0.004
6047 Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1A PDE1A 0.0039
694 Matrix protein 2 M 0.0039
360 Ribonucleoside-diphosphate reductase large subunit RRM1 0.0039
504 Mast/stem cell growth factor receptor KIT 0.0038
153 Dopamine beta-hydroxylase DBH 0.0038
6031 Cytochrome P450 3A43 CYP3A43 0.0038
319 Opioid receptor, sigma 1 OPRS1 0.0038
5692 Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1B PDE1B 0.0037
592 Carbonic anhydrase 4 CA4 0.0037
233 Potassium channel subfamily K member 2 KCNK2 0.0035
427 Substance-P receptor TACR1 0.0034
6506 Stathmin-4 STMN4 0.0033
173 Toll-like receptor 7 TLR7 0.0033
238 Peroxisome proliferator-activated receptor gamma PPARG 0.0033
817 DNA topoisomerase 2-alpha TOP2A 0.0033
738 Monocarboxylate transporter 1 SLC16A1 0.0033
950 Alpha platelet-derived growth factor receptor PDGFRA 0.0032
4199 Sphingosine 1-phosphate receptor Edg-8 S1PR5 0.0031
1284 Nuclear receptor subfamily 1 group I member 2 NR1I2 0.003
762 Voltage-dependent calcium channel subunit alpha-2/delta-1 CACNA2D1 0.003
620 Bifunctional dihydrofolate reductase-thymidylate synthase Not Available 0.003
1709 Canalicular multispecific organic anion transporter 2 ABCC3 0.0029
228 Beta platelet-derived growth factor receptor PDGFRB 0.0029
6141 Sodium/bile acid cotransporter SLC10A1 0.0029
565 Extracellular calcium-sensing receptor CASR 0.0028
462 Intermediate conductance calcium-activated potassium channel protein 4 KCNN4 0.0028
17 Proto-oncogene tyrosine-protein kinase ABL1 ABL1 0.0028
1864 RET proto-oncogene RET 0.0028
1950 Epithelial discoidin domain-containing receptor 1 DDR1 0.0028
6094 BCR/ABL fusion protein isoform X9 BCR/ABL fusion 0.0028
6170 ATP-binding cassette sub-family A member 3 ABCA3 0.0028
392 Voltage-dependent P/Q-type calcium channel subunit alpha-1A CACNA1A 0.0027
1995 Sodium channel protein type 9 subunit alpha SCN9A 0.0027
357 Carbonic anhydrase 2 CA2 0.0026
3804 Sodium channel protein type 4 subunit alpha SCN4A 0.0026
6142 Solute carrier family 22 member 8 SLC22A8 0.0025
1374 Natriuretic peptides B NPPB 0.0025
1827 Gap junction alpha-1 protein GJA1 0.0025
230 ATP-binding cassette transporter sub-family C member 8 ABCC8 0.0025
1908 Vascular cell adhesion protein 1 VCAM1 0.0025
891 Dihydropteroate synthase folP 0.0025
5359 Dihydropteroate synthase folP 0.0025
7175 Dihydropteroate synthase sulI 0.0025
751 Potassium channel subfamily K member 6 KCNK6 0.0025
161 Tubulin beta chain TUBB 0.0024
312 Tubulin beta chain TUB2 0.0024
3937 Fatty-acid amide hydrolase FAAH 0.0024
1974 Oligopeptide transporter, kidney isoform SLC15A2 0.0024
6102 Arylamine N-acetyltransferase 2 NAT2 0.0023
385 Potassium-transporting ATPase alpha chain 1 ATP4A 0.0022
951 Macrophage colony-stimulating factor 1 receptor CSF1R 0.0022
194 NADH dehydrogenase [ubiquinone] 1 subunit C2 NDUFC2 0.0021
952 Dipeptidyl peptidase 4 DPP4 0.0021
63 Malate dehydrogenase mdh 0.0021
2329 Malate dehydrogenase mdh 0.0021
3445 Malate dehydrogenase mdh 0.0021
4420 Malate dehydrogenase mdh 0.0021
4438 Malate dehydrogenase mdh 0.0021
1768 Guanine nucleotide-binding protein G(I)/G(S)/G(O) gamma-2 subunit GNG2 0.002
1581 G protein-activated inward rectifier potassium channel 2 KCNJ6 0.002
1268 Neuropeptide S receptor NPSR1 0.002
1571 G protein-activated inward rectifier potassium channel 1 KCNJ3 0.002
365 Dihydrofolate reductase DHFR 0.002
2381 Dihydrofolate reductase DFR1 0.002
2833 Dihydrofolate reductase Not Available 0.002
2931 Dihydrofolate reductase folA 0.002
3544 Dihydrofolate reductase folA 0.002
3682 Dihydrofolate reductase folA 0.002
6642 Dihydrofolate reductase folA 0.002
6756 Dihydrofolate reductase dfrA 0.002
4203 Histamine N-methyltransferase HNMT 0.0019
6148 Multidrug resistance-associated protein 7 ABCC10 0.0019
871 Glucocorticoid receptor NR3C1 0.0019
251 Alcohol dehydrogenase 1A ADH1A 0.0019
200 Carnitine O-palmitoyltransferase 2, mitochondrial CPT2 0.0019
451 Carnitine O-palmitoyltransferase I, liver isoform CPT1A 0.0019
893 [Citrate [pro-3S]-lyase] ligase citC 0.0018
845 Pyruvate dehydrogenase [cytochrome] poxB 0.0018
327 Glutathione reductase gor 0.0018
5110 Glutathione reductase GR2 0.0018
1178 Adenosine A2a receptor ADORA2A 0.0018
748 5'-AMP-activated protein kinase catalytic subunit alpha-1 PRKAA1 0.0018
6073 Potassium channel subfamily K member 9 KCNK9 0.0018
6072 Potassium channel subfamily K member 3 KCNK3 0.0018
650 Aldo-keto reductase family 1 member C3 AKR1C3 0.0017
4160 Voltage-dependent calcium channel subunit alpha-2/delta-2 CACNA2D2 0.0017
146 Androgen receptor AR 0.0016
444 Alcohol dehydrogenase 1B ADH1B 0.0016
4228 Keratin, type II cytoskeletal 7 KRT7 0.0016
6220 Aryl hydrocarbon receptor AHR 0.0016
1629 Transcription factor AP-1 JUN 0.0016
3970 Voltage-dependent N-type calcium channel subunit alpha-1B CACNA1B 0.0015
982 Cocaine- and amphetamine-regulated transcript protein CARTPT 0.0015
4604 Liver carboxylesterase 1 CES1 0.0015
3086 Plasmepsin-2 Not Available 0.0014
373 Transthyretin TTR 0.0014
485 cGMP-inhibited 3',5'-cyclic phosphodiesterase A PDE3A 0.0014
517 Alcohol dehydrogenase 1C ADH1C 0.0014
4148 Serine/threonine-protein kinase mTOR MTOR 0.0014
208 DNA-directed RNA polymerase beta' chain rpoC 0.0014
5774 DNA-directed RNA polymerase beta' chain rpoC 0.0014
6143 Solute carrier family 22 member 7 SLC22A7 0.0013
3404 Exotoxin A eta 0.0013
73 Prostaglandin E2 receptor, EP1 subtype PTGER1 0.0013
2207 Rhodopsin RHO 0.0013
860 Nicotinamide N-methyltransferase NNMT 0.0013
699 Nicotinic acid receptor 1 GPR109A 0.0013
928 Nicotinic acid receptor 2 GPR109B 0.0013
583 Nicotinate-nucleotide pyrophosphorylase [carboxylating] QPRT 0.0013
2442 Nicotinate-nucleotide pyrophosphorylase [carboxylating] nadC 0.0013
2459 Nicotinate-nucleotide pyrophosphorylase [carboxylating] nadC 0.0013
1010 Cytochrome P450 51A1 CYP51A1 0.0012
232 Corticosteroid-binding globulin SERPINA6 0.0012
276 Sodium- and chloride-dependent GABA transporter 1 SLC6A1 0.0012
3856 Fibroblast growth factor receptor 3 FGFR3 0.0012
5766 NAD-dependent deacetylase sirtuin-5 SIRT5 0.0012
473 L-lactate dehydrogenase A chain LDHA 0.0011
6014 Cytochrome P450 2A13 CYP2A13 0.0011
707 72 kDa type IV collagenase MMP2 0.0011
2290 ADP-ribosyl cyclase 2 BST1 0.001
614 Progesterone receptor PGR 0.001
2300 Lysozyme E 0.001
3633 Lysozyme R 0.001
5597 Lysozyme 17 0.001
407 Vascular endothelial growth factor receptor 2 KDR 0.001
6181 UDP-glucuronosyltransferase 1-8 UGT1A8 0.001
4311 tRNA TRDMT1 0.001
4325 tRNA trmD 0.001
4328 tRNA trmD 0.001
6080 Neuronal acetylcholine receptor subunit alpha-5 CHRNA5 0.001
6082 Neuronal acetylcholine receptor subunit beta-3 CHRNB3 0.001
948 Neuronal acetylcholine receptor subunit beta-2 CHRNB2 0.001
243 Ribosyldihydronicotinamide dehydrogenase [quinone] NQO2 0.001
260 Cytochrome P450 51 ERG11 0.001
761 Cytochrome P450 51 ERG11 0.001
3163 Cytochrome P450 51 cyp51 0.001
144 Hemoglobin subunit alpha HBA1 0.001
518 Peroxidase/catalase T katG 0.001
777 Tumor necrosis factor TNF 0.0009
6154 Multidrug and toxin extrusion protein 1 SLC47A1 0.0009
6081 Neuronal acetylcholine receptor subunit alpha-6 CHRNA6 0.0009
4097 Neuronal acetylcholine receptor subunit alpha-9 CHRNA9 0.0009
3126 Poly [ADP-ribose] polymerase 1 PARP1 0.0009
1064 DNA (cytosine-5)-methyltransferase 1 DNMT1 0.0009
563 Thyroid peroxidase TPO 0.0009
147 Aldehyde dehydrogenase, mitochondrial ALDH2 0.0009
65 Matrix metalloproteinase-9 Not Available 0.0009
26 Vascular endothelial growth factor receptor 3 FLT4 0.0009
295 Carbonic anhydrase 1 CA1 0.0009
741 Potassium voltage-gated channel subfamily KQT member 1 KCNQ1 0.0009
4122 Histone deacetylase 2 HDAC2 0.0009
16 Adenosine A1 receptor ADORA1 0.0009
32 Vascular endothelial growth factor receptor 1 FLT1 0.0009
634 Squalene monooxygenase SQLE 0.0009
7196 Squalene monooxygenase ERG1 0.0009
204 cGMP-specific 3',5'-cyclic phosphodiesterase PDE5A 0.0009
6078 Neuronal acetylcholine receptor subunit beta-4 CHRNB4 0.0009
1262 Corticotropin-lipotropin POMC 0.0008
1341 Histamine H3 receptor HRH3 0.0008
3932 Glutathione S-transferase A2 GSTA2 0.0008
1192 Sulfotransferase 1A1 SULT1A1 0.0008
778 Cysteinyl leukotriene receptor 1 CYSLTR1 0.0008
522 26S proteasome non-ATPase regulatory subunit 2 PSMD2 0.0008
515 26S proteasome non-ATPase regulatory subunit 1 PSMD1 0.0008
1457 Long-chain-fatty-acid--CoA ligase 4 ACSL4 0.0008
165 FL cytokine receptor FLT3 0.0008
244 Angiotensin-converting enzyme ACE 0.0008
6126 Carbonic anhydrase 7 CA7 0.0008
6212 Tubulin gamma-1 chain TUBG1 0.0008
6210 Tubulin delta chain TUBD1 0.0008
6211 Tubulin epsilon chain TUBE1 0.0008
4177 Proto-oncogene tyrosine-protein kinase receptor ret RET 0.0008
500 Monocarboxylate transporter 4 SLC16A3 0.0008
70 Type-1 angiotensin II receptor AGTR1 0.0008
6137 Multidrug resistance-associated protein 6 ABCC6 0.0008
606 Cytochrome P450 27, mitochondrial CYP27A1 0.0007
541 cAMP-specific 3',5'-cyclic phosphodiesterase 4B PDE4B 0.0007
6152 Solute carrier organic anion transporter family member 2A1 SLCO2A1 0.0007
3854 Basic fibroblast growth factor receptor 1 FGFR1 0.0007
122 P2Y purinoceptor 12 P2RY12 0.0007
6136 Multidrug resistance-associated protein 5 ABCC5 0.0007
581 Cytochrome P450 2R1 CYP2R1 0.0007
6038 Retinal cone rhodopsin-sensitive cGMP 3',5'-cyclic phosphodiesterase subunit gamma PDE6H 0.0007
4773 Deoxycytidine kinase DCK 0.0007
2222 Equilibrative nucleoside transporter 1 SLC29A1 0.0007
1992 Vitamin D-binding protein GC 0.0007
368 Enoyl-[acyl-carrier-protein] reductase [NADH] inhA 0.0007
3228 Enoyl-[acyl-carrier-protein] reductase [NADH] fabI 0.0007
3678 Enoyl-[acyl-carrier-protein] reductase [NADH] fabI 0.0007
6856 Enoyl-[acyl-carrier-protein] reductase [NADH] fabI 0.0007
7 Nitric oxide synthase, inducible NOS2 0.0007
6037 Retinal rod rhodopsin-sensitive cGMP 3',5'-cyclic phosphodiesterase subunit gamma PDE6G 0.0007
737 Mineralocorticoid receptor NR3C2 0.0006
976 Platelet glycoprotein IX GP9 0.0006
4103 Proteasome subunit beta type 2 PSMB2 0.0006
4102 Proteasome subunit beta type 5 PSMB5 0.0006
4101 Proteasome subunit beta type 1 PSMB1 0.0006
1630 Integrin beta-2 ITGB2 0.0006
2450 Tyrosine-protein kinase ITK/TSK ITK 0.0006
2216 Fibroblast growth factor receptor 4 FGFR4 0.0006
806 Sodium/potassium-transporting ATPase alpha-1 chain ATP1A1 0.0006
814 Ryanodine receptor 1 RYR1 0.0006
511 5-hydroxytryptamine 1F receptor HTR1F 0.0006
6146 High affinity copper uptake protein 1 SLC31A1 0.0006
2449 Tubulin alpha-3 chain TUBA1A 0.0006
6046 Voltage-gated calcium channel beta 1 subunit splice variant CavB1d CACNB1 0.0006
6048 Troponin C, skeletal muscle TNNC2 0.0005
543 Penicillin-binding protein 1B mrcB 0.0005
6186 Penicillin-binding protein 1B ponB 0.0005
6822 Penicillin-binding protein 1b pbp1b 0.0005
6844 Penicillin-binding protein 1b pbp1b 0.0005
645 Penicillin-binding protein 1A mrcA 0.0005
5805 Penicillin-binding protein 1A ponA 0.0005
6185 Penicillin-binding protein 1A mrcA 0.0005
6799 Penicillin-binding protein 1A pbpA 0.0005
268 Adenosine A2b receptor ADORA2B 0.0005
159 Penicillin-binding protein 2B penA 0.0005
6121 Penicillin-binding protein 2B penA 0.0005
6044 Serum paraoxonase/lactonase 3 PON3 0.0005
1024 Solute carrier family 22 member 11 SLC22A11 0.0005
6045 Voltage-dependent calcium channel subunit alpha-2/delta-3 CACNA2D3 0.0005
856 Vitamin D3 receptor VDR 0.0005
572 Integrin alpha-L ITGAL 0.0005
3868 Calcineurin subunit B isoform 2 PPP3R2 0.0005
421 Calcium signal-modulating cyclophilin ligand CAMLG 0.0005
6824 Tyrosine-protein kinase Lyn LYN 0.0005
1275 Estrogen sulfotransferase SULT1E1 0.0004
3802 Sodium channel protein type 2 subunit alpha SCN2A 0.0004
136 Estrogen receptor ESR1 0.0004
760 Fibroblast growth factor 1 FGF1 0.0004
6931 Calcium-activated potassium channel subunit beta-1 KCNMB1 0.0004
6933 Calcium-activated potassium channel subunit beta-4 KCNMB4 0.0004
6932 Calcium-activated potassium channel subunit beta-3 KCNMB3 0.0004
6934 Small conductance calcium-activated potassium channel protein 1 KCNN1 0.0004
6935 Small conductance calcium-activated potassium channel protein 2 KCNN2 0.0004
6936 Small conductance calcium-activated potassium channel protein 3 KCNN3 0.0004
823 Fibroblast growth factor receptor 2 FGFR2 0.0004
291 Nitric-oxide synthase, endothelial NOS3 0.0004
5934 Cytochrome P450 26A1 CYP26A1 0.0004
6177 UDP-glucuronosyltransferase 1-10 UGT1A10 0.0004
6172 ATP-binding cassette sub-family B member 8, mitochondrial ABCB8 0.0004
5463 Calcium-activated potassium channel subunit beta 2 KCNMB2 0.0004
40 RAF proto-oncogene serine/threonine-protein kinase RAF1 0.0004
1524 Peptidyl-prolyl cis-trans isomerase A PPIA 0.0004
6700 Peptidyl-prolyl cis-trans isomerase A ppiA 0.0004
1971 cAMP-specific 3',5'-cyclic phosphodiesterase 4A PDE4A 0.0004
84 Nuclear receptor 0B1 NR0B1 0.0004
337 NADH dehydrogenase [ubiquinone] iron-sulfur protein 7, mitochondrial NDUFS7 0.0004
214 NADH dehydrogenase [ubiquinone] iron-sulfur protein 3, mitochondrial NDUFS3 0.0004
803 NADH dehydrogenase [ubiquinone] iron-sulfur protein 2, mitochondrial NDUFS2 0.0004
3957 Adenosine deaminase ADA 0.0004
6168 Solute carrier family 22 member 16 SLC22A16 0.0003
937 Proto-oncogene tyrosine-protein kinase LCK LCK 0.0003
6861 Alcohol dehydrogenase [NADP+] AKR1A1 0.0003
6140 Ileal sodium/bile acid cotransporter SLC10A2 0.0003
469 Annexin A1 ANXA1 0.0003
933 Proto-oncogene tyrosine-protein kinase Src SRC 0.0003
2157 NAD(P)H dehydrogenase [quinone] 1 NQO1 0.0002
869 Estrogen receptor beta ESR2 0.0002
76 Nitric-oxide synthase, brain NOS1 0.0002
↑